Ganga Pharmaceuticals Ltd
Ganga Pharmaceuticals Ltd (GANGAPHARM) last reported results for the quarter ended Mar 2026, with sales of ₹1.46 crore and net profit of ₹0.08 crore. The stock last traded at ₹12.5, a market capitalisation of ₹7.39 crore, on a P/E of 73.9. Over the past 52 weeks the stock has ranged between ₹9.35 and ₹14. Figures are as of 6 Oct 2026 and are not real time.
Ganga Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹12.5
- Market cap
- ₹7.39 cr
- Stock P/E
- 73.9
- Book value
- ₹14.1
- ROE
- 1.30%
- ROCE
- 2.90%
- Dividend yield
- 0.00%
- 52w high / low
- 14.0/9.35
Metrics as of 6 Oct 2026. Not real time.
Track Ganga Pharmaceuticals Ltd
Cruxal reads every Ganga Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ganga Pharmaceuticals Ltd growth and returns
- 10 Years
- 1%
- 5 Years
- 3%
- 3 Years
- 3%
- TTM
- 8%
- 10 Years
- 7%
- 5 Years
- 38%
- 3 Years
- 36%
- TTM
- 25%
- 10 Years
- 5%
- 5 Years
- 20%
- 3 Years
- 5%
- 1 Year
- -14%
- 10 Years
- 2%
- 5 Years
- 1%
- 3 Years
- 1%
- Last Year
- 1%
Ganga Pharmaceuticals Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹1.46 cr, up 9.8% from ₹1.33 cr a year earlier. Net profit was ₹0.08 cr, up 33.3% year on year.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.35 | 1.23 | 1.32 | 1.42 | 1.31 | 1.33 | 1.37 | 1.46 |
| Expenses | 1.28 | 1.3 | 1.27 | 1.41 | 1.42 | 1.33 | 1.39 | 1.39 |
| Operating profit | 0.07 | -0.07 | 0.05 | 0.01 | -0.11 | 0 | -0.02 | 0.07 |
| OPM % | 5.19% | -5.69% | 3.79% | 0.70% | -8.40% | 0.00% | -1.46% | 4.79% |
| Other income | 0.12 | 0.18 | 0.09 | 0.15 | 0.29 | 0.14 | 0.15 | 0.13 |
| Interest | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 | 0.07 | 0.07 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 |
| Profit before tax | 0.04 | 0.01 | 0.02 | 0.05 | 0.07 | 0.03 | 0.03 | 0.1 |
| Tax % | 25.00% | 0.00% | 50.00% | 20.00% | 57.14% | -66.67% | 33.33% | 20.00% |
| Net profit | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 | 0.02 | 0.08 |
| EPS (₹) | 0.07 | 0.02 | 0.05 | 0.06 | 0.04 | 0.12 | 0.03 | 0.14 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ganga Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.58 | 2.48 | 2.67 |
| Operating profit | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0 | 0.05 | -0.12 | 0.04 |
| OPM % | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0.00% | 1.94% | -4.84% | 1.50% |
| Net profit | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 | 0.1 |
| EPS (₹) | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 | 0.17 |
TTM is the trailing twelve months to the most recent quarter.
Ganga Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.40 |
| Borrowings | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | 1.09 |
| Other liabilities | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | 0.25 |
| Total liabilities | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 9.65 |
| Fixed assets | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.65 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Other assets | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9.00 |
| Total assets | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 9.65 |
As reported by the company. Total assets equal total liabilities by construction.
Ganga Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.05 | 0.24 | 0.11 | -0.31 | -0.18 | -0.21 | -0.04 | -1.26 | -0.58 | -1.31 |
| Cash from investing | 0.62 | -0.14 | 0.28 | 0.37 | 0.28 | 0.19 | 0.49 | 0.13 | 1.18 | 0.24 |
| Cash from financing | -0.33 | -0.36 | -0.45 | -0.29 | -0.10 | 0.03 | -0.44 | 1.14 | -0.33 | 0.82 |
| Net cash flow | 0.33 | -0.26 | -0.05 | -0.22 | 0.00 | 0.01 | 0.01 | 0.00 | 0.27 | -0.24 |
| Free cash flow | 0.01 | -0.02 | 0.08 | -0.32 | -0.20 | -0.22 | -0.05 | -1.28 | -0.68 | -1.35 |
| CFO / operating profit | 29% | 88% | 40% | -66% | -567% | -500% | — | -2,480% | 467% | -3,200% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Ganga Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% | 2.90% |
| Debtor days | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 130.16 | 133.93 | 128.50 |
| Inventory days | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 | 328.50 |
| Days payable | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 | 33.69 |
| Cash conversion cycle | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 463.04 | 403.19 | 423.31 |
| Working capital days | 428.84 | 417.14 | 387.96 | 449.23 | 477.56 | 503.45 | 477.31 | 639.46 | 731.47 | 855.77 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Ganga Pharmaceuticals Ltd shareholding pattern
Promoters held 50.91% at Mar 2026, down from 56.02% at Mar 2024.
| % held | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.71% | 66.71% | 66.71% | 56.02% | 56.02% | 56.02% | 50.91% | 50.91% |
| Public | 33.29% | 33.29% | 33.28% | 43.98% | 43.98% | 43.98% | 49.09% | 49.09% |
| No. of shareholders | 355 | 356 | 359 | 363 | 365 | 368 | 366 | 365 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ganga Pharmaceuticals Ltd corporate filings
- Ganga Pharmaceuticals Limited announces re-appointment of Mr. Bharat Brijmohan Sharma as Managing DirectorCompany Updatelow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has formally announced the re-appointment of Mr. Bharat…
Read the full analysis - Ganga Pharmaceuticals Limited announces successful conclusion of 37th Annual General Meeting and re-appointment of Managing DirectorAGM/EGMlow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has successfully concluded its 37th Annual General Meeting…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- Ganga Pharmaceuticals Limited concludes 37th Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has successfully concluded its 37th Annual General Meeting…
Read the full analysis - Ganga Pharmaceuticals Ltd announces newspaper publication for 37th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Ganga Pharmaceuticals Ltd has fulfilled regulatory requirements under Regulation 30 of…
Read the full analysis - Ganga Pharmaceuticals Limited announces 37th Annual General Meeting scheduled for September 26, 2026Company Updatelow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has issued a routine regulatory disclosure regarding the…
Read the full analysis - Ganga Pharmaceuticals Limited announces 37th AGM and re-appointment of Managing DirectorAGM/EGMlow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has issued a notice for its 37th Annual General Meeting…
Read the full analysis - Ganga Pharmaceuticals Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Ganga Pharmaceuticals Ltd has submitted its Annual Report for the financial year 2025-26…
Read the full analysis - Ganga Pharmaceuticals Limited Announces 37th Annual General Meeting and Releases FY 2025-26 Annual ReportAGM/EGMlow impact
Cruxal's analysis: Ganga Pharmaceuticals Limited has scheduled its 37th Annual General Meeting for September…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.